Effect of evacetrapib on cardiovascular outcomes in patients with high-risk cardiovascular disease.
作者信息
Aronow Wilbert S
机构信息
Department of Medicine, Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA.
出版信息
J Thorac Dis. 2017 Jul;9(7):1822-1825. doi: 10.21037/jtd.2017.06.106.
Abstract
摘要
相似文献
1
Effect of evacetrapib on cardiovascular outcomes in patients with high-risk cardiovascular disease.依折麦布对高危心血管疾病患者心血管结局的影响。
J Thorac Dis. 2017 Jul;9(7):1822-1825. doi: 10.21037/jtd.2017.06.106.
2
ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study.ADCY9 基因变异与高危血管疾病患者应用依维莫司的心血管结局：一项巢式病例对照研究。
JAMA Cardiol. 2018 May 1;3(5):401-408. doi: 10.1001/jamacardio.2018.0569.
3
No cardiovascular benefit with evacetrapib - is this the end of the road for the 'cetrapibs'?依折麦布无心血管益处——“塞曲匹布类药物”就此终结？
Expert Opin Pharmacother. 2017 Oct;18(14):1439-1442. doi: 10.1080/14656566.2017.1365838. Epub 2017 Aug 14.
4
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.依维莫司和高危血管疾病的心血管结局。
N Engl J Med. 2017 May 18;376(20):1933-1942. doi: 10.1056/NEJMoa1609581.
5
Evacetrapib: Another CETP Inhibitor for Dyslipidemia With No Clinical Benefit.依伐卡托：一种对血脂异常无临床益处的新型胆固醇酯转运蛋白抑制剂
Cardiol Rev. 2017 Mar/Apr;25(2):43-52. doi: 10.1097/CRD.0000000000000137.
6
Evacetrapib reduces preβ-1 HDL in patients with atherosclerotic cardiovascular disease or diabetes.依维莫司降低动脉粥样硬化性心血管疾病或糖尿病患者的前β-1 高密度脂蛋白。
Atherosclerosis. 2019 Jun;285:147-152. doi: 10.1016/j.atherosclerosis.2019.04.211. Epub 2019 Apr 14.
7
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.依泽替米贝单药治疗或与他汀类药物联合治疗对高密度脂蛋白胆固醇和低密度脂蛋白胆固醇的影响：一项随机对照试验。
JAMA. 2011 Nov 16;306(19):2099-109. doi: 10.1001/jama.2011.1649.
8
Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial.胆固醇酯转运蛋白抑制、他汀类药物或依折麦布对脂质因子的比较效应：ACCENTUATE试验。
Atherosclerosis. 2017 Jun;261:12-18. doi: 10.1016/j.atherosclerosis.2017.04.008. Epub 2017 Apr 8.
9
Efficacy and Safety of Evacetrapib for Modifying Plasma Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.依伐卡托改善血脂水平的疗效与安全性：随机对照试验的系统评价与荟萃分析
Curr Pharm Des. 2016;22(5):595-608. doi: 10.2174/1381612822666151125000035.
10
Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients.依伐卡托单独使用或与他汀类药物联合使用可降低轻度高胆固醇血症患者的脂蛋白(a)以及总低密度脂蛋白和小低密度脂蛋白颗粒浓度。
J Clin Lipidol. 2016 May-Jun;10(3):519-527.e4. doi: 10.1016/j.jacl.2015.11.014. Epub 2015 Dec 18.
本文引用的文献
1
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.依维莫司和高危血管疾病的心血管结局。
N Engl J Med. 2017 May 18;376(20):1933-1942. doi: 10.1056/NEJMoa1609581.
2
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics.阿那曲泊帕通过脂质修饰作用的随机评估（REVEAL）——一项针对已患血管疾病人群的阿那曲泊帕临床疗效的大规模、随机、安慰剂对照试验：试验设计、招募及基线特征
Am Heart J. 2017 May;187:182-190. doi: 10.1016/j.ahj.2017.02.021. Epub 2017 Feb 21.
3
Effects of Torcetrapib and Statin Treatment on ApoC-III and Apoprotein-Defined Lipoprotein Subclasses (from the ILLUMINATE Trial).托彻普和他汀类药物治疗对载脂蛋白C-III及载脂蛋白定义的脂蛋白亚类的影响（来自ILLUMINATE试验）
Am J Cardiol. 2017 Jun 1;119(11):1753-1756. doi: 10.1016/j.amjcard.2017.02.049. Epub 2017 Mar 18.
4
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.依洛尤单抗与心血管疾病患者的临床结局。
N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
5
Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP as a Target to Lower CVD Risk: Suspension of Disbelief?胆固醇酯转运蛋白抑制是降低心血管风险的有效策略吗？作为降低心血管疾病风险靶点的胆固醇酯转运蛋白：难以置信？
Circulation. 2015 Aug 4;132(5):433-40. doi: 10.1161/CIRCULATIONAHA.115.014026.
6
Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce Cardiovascular Risk: The Pro Case.胆固醇酯转运蛋白抑制是降低心血管风险的有效策略吗？胆固醇酯转运蛋白抑制作为降低心血管风险的策略：支持的理由。
Circulation. 2015 Aug 4;132(5):423-32. doi: 10.1161/CIRCULATIONAHA.114.014025.
7
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.依折麦布联合他汀类药物治疗急性冠脉综合征。
N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3.
8
Lipid-lowering therapy in older persons.老年人的降脂治疗。
Arch Med Sci. 2015 Mar 16;11(1):43-56. doi: 10.5114/aoms.2015.48148. Epub 2015 Jan 8.
9
Effects of extended-release niacin with laropiprant in high-risk patients.烟酸缓释剂联合拉罗匹仑在高危患者中的作用。
N Engl J Med. 2014 Jul 17;371(3):203-12. doi: 10.1056/NEJMoa1300955.
10
Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges.高密度脂蛋白功能向临床实践的转化：当前前景与未来挑战。
Circulation. 2013 Sep 10;128(11):1256-67. doi: 10.1161/CIRCULATIONAHA.113.000962.
Zotero 插件